^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    CONFIRM anti-Total c-MET (SP44) Rabbit Monoclonal Primary Antibody

    Company:
    Roche
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    4ms
    TeliMET NSCLC-01: A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3; Trial primary completion date: Jun 2025 --> Mar 2028
    Trial primary completion date • Adverse events • Metastases
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    CONFIRM anti-Total c-MET (SP44) Rabbit Monoclonal Primary Antibody
    |
    docetaxel • telisotuzumab vedotin (ABBV-399)
    10ms
    TeliMET NSCLC-01: A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3; Trial completion date: Jul 2026 --> Mar 2028
    Trial completion date • Adverse events • Metastases
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET overexpression
    |
    CONFIRM anti-Total c-MET (SP44) Rabbit Monoclonal Primary Antibody
    |
    docetaxel • telisotuzumab vedotin (ABBV-399)
    10ms
    TeliMET NSCLC-01: A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3; Trial completion date: Mar 2028 --> Jul 2026
    Trial completion date • Adverse events • Metastases
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET overexpression
    |
    CONFIRM anti-Total c-MET (SP44) Rabbit Monoclonal Primary Antibody
    |
    docetaxel • telisotuzumab vedotin (ABBV-399)
    1year
    Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC) (ESMO Asia 2023)
    Enrollment of ≥698 pts is planned across ∼300 sites in ∼40 countries. As of 4 July 2023, 162 sites are actively recruiting in 26 countries including Asia-Pacific countries (China [25 sites], Japan [38 sites], South Korea [5 sites], Taiwan [8 sites], Australia [2 sites]).
    P3 data • Metastases
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR wild-type • EGFR overexpression • MET overexpression
    |
    CONFIRM anti-Total c-MET (SP44) Rabbit Monoclonal Primary Antibody
    |
    docetaxel • telisotuzumab vedotin (ABBV-399)